Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours.

Journal article

Immunotherapies based on reinfusion of autologous cells incubated ex vivo with peptides reconstituted in toxic solvents, such as DMSO, are now performed on a routine basis. However, the toxic effects of the most common solvent used, DMSO, on T cell responses from human PBMCs, have not previously been evaluated in detail. Here, in preparation for a first-in-man human phase I vaccine trial comprising reinfusion of autologous HIV peptide-pulsed PBMCs, human PBMCs from healthy and HIV-infected do...

Expand abstract

Authors: Kloverpris, H; Fomsgaard, A; Handley, A; Ackland, J; Sullivan, M

• Publication status: Published
• Journal: Journal of immunological methods
• Volume: 356
• Issue: 1-2
• Pages: 70-78
• Publication date: 2010-04-01
• DOI: 10.1016/j.jim.2010.01.014
• EISSN: 1872-7905
• ISSN: 0022-1759
• Language: English
• Keywords: Cytokines; T-Lymphocytes; Leukocytes; HIV Seropositivity; Humans; Dimethyl Sulfoxide; Cell Survival; Cells, Cultured; Clinical Trials as Topic; Time Factors; AIDS Vaccines